Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

BME:PUIG
BME:PUIGPersonal Products

Is Saks Global Bankruptcy Exposure Reshaping Credit Risk Perceptions For Puig Brands (BME:PUIG)?

Saks Global’s recent Chapter 11 bankruptcy filing revealed that Puig Brands is an unsecured creditor, with about US$12,000,000 in outstanding receivables tied to the luxury retailer’s restructuring of more than €700,000,000 in debt. This exposure highlights Puig’s credit risk to key distribution partners, raising questions about the timing and extent of any recovery despite Saks securing US$1.75 billion in new financing to keep operations running. Against this backdrop, we’ll explore how...
TSX:GRT.UN
TSX:GRT.UNIndustrial REITs

A Look At Granite Real Estate Investment Trust (TSX:GRT.UN) Valuation After Active Portfolio Moves And Higher Occupancy

Granite Real Estate Investment Trust (TSX:GRT.UN) has been busy reshaping its industrial footprint by acquiring C$292 million of income producing U.S. and UK properties, selling select U.S. assets, and securing leases that bring occupancy to 98%. See our latest analysis for Granite Real Estate Investment Trust. These portfolio moves sit alongside regular distributions and a recent equity program, and the share price has been firming, with a 30 day share price return of 11.94% and a 1 year...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline

CG Oncology (CGON) is back in focus after accelerating the topline data timeline for its Phase 3 PIVOT-006 trial, the first randomized study for intermediate-risk non muscle invasive bladder cancer patients. See our latest analysis for CG Oncology. The accelerated PIVOT-006 timeline sits against a strong recent run, with a 30 day share price return of 40.23% and a 1 year total shareholder return of 88.20%, suggesting momentum has been building around the story. If CG Oncology’s progress has...
TASE:STRS
TASE:STRSFood

Strauss Group (TASE:STRS) Valuation Check After Strong 3 Month And 1 Year Shareholder Returns

Recent performance snapshot Strauss Group (TASE:STRS) has drawn fresh interest after a solid run in the shares, with the stock showing gains over the past week, month and past 3 months alongside a strong 1 year total return. See our latest analysis for Strauss Group. The recent 24.99% 3 month share price return and 69.67% 1 year total shareholder return suggest that momentum has been building, as investors reassess both growth prospects and perceived risks around Strauss Group at a share...
NasdaqGS:TIGO
NasdaqGS:TIGOWireless Telecom

Millicom (TIGO) Is Up 17.1% After UBS Upgrade on Latin America Expansion Ambitions

Earlier this week, UBS analyst Leonardo Olmos upgraded Millicom International Cellular (TIGO) to a buy rating, citing increased confidence in the company’s growth outlook as it expands telecom services across Latin America and pursues acquisitions in Ecuador and Uruguay. This shift in analyst sentiment highlights how Millicom’s regional expansion and service diversification are increasingly shaping market perceptions of its longer-term prospects. We’ll now examine how UBS’s renewed...
SEHK:11
SEHK:11Banks

Is It Too Late To Consider Hang Seng Bank (SEHK:11) After A 74.5% One-Year Rise?

If you are wondering whether Hang Seng Bank's current share price offers good value or not, you are not alone. This article is written with that exact question in mind. The stock closed at HK$154.3, with returns of 0.5% over the last 30 days, 0.3% year to date and 74.5% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage around Hang Seng Bank has focused on its role as one of Hong Kong's major banking institutions...
SEHK:1347
SEHK:1347Semiconductor

Hua Hong Semiconductor (SEHK:1347) Is Up 17.0% After China Tightens Access To Nvidia AI Chips

In recent days, Chinese authorities reportedly moved to limit purchases of Nvidia’s H200 AI chips to special circumstances, while domestic AI developer Zhipu released a new model trained entirely on Huawei-made chips, reinforcing Beijing’s push for greater self-reliance in advanced semiconductors. This combination of tighter controls on foreign AI hardware and tangible progress in homegrown AI chip ecosystems has sharpened investor focus on how domestic foundries like Hua Hong Semiconductor...
SEHK:1972
SEHK:1972Real Estate

Can Bank of America’s Brighter View Reshape Swire Properties’ (SEHK:1972) Two-Speed Rental Narrative?

Earlier this year, Bank of America raised its forecast for Hong Kong home prices for 2026 and 2027 and expressed a positive stance on Swire Properties, expecting a profit rebound supported by recovering residential and commercial real estate markets in key districts. A key nuance is Bank of America’s view that rising office rents in Central and Tsim Sha Tsui, contrasted with pressure in Kowloon and Hong Kong Island East, could create a two-speed rental landscape that matters for Swire...
NasdaqGS:CNTA
NasdaqGS:CNTABiotechs

How Centessa’s OX2R Expansion, Leadership Shifts and $250M Raise At Centessa Pharmaceuticals (CNTA) Has Changed Its Investment Story

In recent days, Centessa Pharmaceuticals reported new preclinical data showing its selective OX2R agonist reduced behavioral despair and improved wakefulness in animal models of major depressive disorder, while also outlining plans to broaden its orexin pipeline across neuropsychiatric conditions with high unmet need. Coupled with strong analyst support, leadership changes, and a planned US$250,000,000 public offering to fund late-stage trials, these developments highlight how Centessa is...
SEHK:2498
SEHK:2498Electronic

Is Robosense Technology (SEHK:2498) Pricing Reflect Its Recent Share Performance?

If you are wondering whether Robosense Technology’s recent share price reflects its real value, you are not alone. That is exactly what this article will help you unpack. The stock last closed at HK$39.86, with returns of 2.8% over 7 days, 10.4% over 30 days, 6.9% year to date and 35.6% over the last year. This performance has put the question of valuation firmly on the table. Recent coverage around Robosense Technology has focused on its position in the Hong Kong tech sector and investor...
TSX:DIR.UN
TSX:DIR.UNIndustrial REITs

Assessing Dream Industrial REIT (TSX:DIR.UN) Valuation As Leasing Demand Recovers And Rate Expectations Ease

Dream Industrial Real Estate Investment Trust (TSX:DIR.UN) is back in focus as its units respond to stronger industrial leasing demand and a more dovish interest rate outlook, which is reinforcing interest in its logistics focused portfolio. See our latest analysis for Dream Industrial Real Estate Investment Trust. At a unit price of CA$13.52, Dream Industrial REIT has seen its 30 day share price return of 7.22% build on a 90 day gain of 10.46%. Its 1 year total shareholder return of 22.73%...
NasdaqGS:LX
NasdaqGS:LXConsumer Finance

How Investors May Respond To LexinFintech (LX) Spotlighted As Fundamentally Driven Penny Stock In China Finance

Recently, LexinFintech Holdings was featured in research on promising penny stocks, highlighting its strong financial health rating and position within China's consumer finance sector. An interesting angle from this coverage is that LexinFintech is being framed as a lower-priced entry point where fundamentals, rather than speculation, are the primary focus for investors. Against this backdrop of attention on LexinFintech’s financial strength, we’ll examine how this recognition may influence...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook

Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar Xeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock. See our latest analysis for Xeris Biopharma Holdings. The updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share...